• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Beschrieben werden neue Tetraoxodiazabicyclo-(3,3,1 -nonane der allgemeinen Formel (I) in welcher R, bis R4 und Z, und Z2 die in der Beschreibung angegebene Bedeutung besitzen und weiche wertvolle Zwischenprodukte zur Herstellung pharmakologisch wirksamer N,N'-disubstituierter Diazabicyclo-(3,3,1)-nonane darstellen, und ihre Herstellung.
    公开号:SU1272989A3
    申请号:SU833646751
    申请日:1983-09-16
    公开日:1986-11-23
    发明作者:Шен Уве；Хахмайстер Бернд；Кербах Вольфганг；Кюль Ульрих；Бушманн Герд
    申请人:Кали-Хеми Фарма Гмбх (Фирма)；
    IPC主号:
    专利说明:


    04
    This invention relates to a process for the preparation of new derivatives of diaeabicyclo (3.3.1) nonanes of the general formula
    (I)
    where R, and RJ - independently of
    friend C, -C-alkyl or -alkylene;
    R, and Cc, independently of each other, are C, -C-alkyl or C-Su-alkylene, provided that,) contain at least five carbon atoms in total.
    The purpose of the invention is to develop a method for producing derivatives of diazabicyclo (3.3.1) nonanes, possessing (their improved antiarrhythmic action compared to the structural analogue N, N -9,9-tetramethyldiaeabicyclo (3,3,1) nonan.
    Example 1. General procedure for the reduction of compounds of the general formula
    Ri- ((II)
    where R, -R have the indicated meanings.
    In a three-necked flask load O, 1 mol of lithium-aluminum hydride in 100 ml of a mixture of absolute tetrahydrofuran and absolute toluene (7: 3). When the temperature of the oil bath reaches 80 ° C, 0.025 mol of the compound of formula (II) is slowly added dropwise to the flask in a solution of absolute toluene and tetrahydrofuran (7: 3). The reaction mixture was kept at 120 ° C for 2-4 hours. After this, to the reaction mass was added (based on 1 g of LiAlH used) 1 ml of water, 1 ml of a 20% aqueous solution of sodium hydroxide, 1 ml of water. The separated precipitate is filtered off, the mother liquor is extracted with methylene chloride, and dried over magnesium sulfate. The solvent is removed in vacuo. The compounds obtained are listed in Table. 1. Examples 2-5. Similarly, the reduction of tetraoxo compounds (II) is carried out under conditions of lead. Data in the table. 2,
    The effect of the active substance on myocardial oxygen consumption was investigated on animals 1X,
    In tab. Figure 3 shows the effect of compound 1a on cardiac muscle contraction (FRQ), systolytic blood pressure (PS) and double product (DP) of anesthetized rats.
    As can be seen from the table. 3 active substance 1a reproduces double
    the product of heart rate and systolytic blood pressure thus leads to an accumulation of oxygen in the heart. This effect takes place both after intravenous and after intradodenal administration (i, d).
    The antiarrhythmic effect of compounds 1a-1e was determined on intact experimental animals with experimentally induced heart disorders. With continuous intravenous infusion of aconitin in rats, a significant disturbance in the sequence of heartbeats can be seen on the electrocardiogram, such as ventricular extrasystoles.
    The effect of the active substance on male rats weighing 280–350 g is illustrated in Table. 4. The difference in those times is indicated in percent when compared with the control experiment, where the active substance is replaced by vehickel (isotope NaCl), after intravenous administration of the active substance at a dosage of 6.0 µmol / kg i, v. one twentieth LDj i.p. defined for mice, (LD, -gp.o, is
    0 1038 µmol / kg) and subsequent infusion of a constant per unit time dose of aconitine to the occurrence of ventricular extrasystoles (ES). For comparison, Table 2 shows the effect of an equitoxic dose of lidocaine. used in the clinic, antiarrhythmics. The antiarrhythmic effect of new effective substances has also been proved experimentally by determining the functional refractory time of the left atrium on female individuals of white guinea pigs weighing 300-400 g using a paired electrical stimulator or taking into account the Goviere method. All used in antiarrhythmic therapy The chemical structure is characterized by a prolonged functional refractory time. Additionally, the effect of substances on the contraction force of the heart muscle is possible.
    In tab. 5 indicates a FRP of 125% such concentration, at which 18 minutes after the administration of the substance, the functional refractory time is extended to 125%, or as F 75% of the corresponding concentration, which reduces the contractile force by 75% of the initial value. In addition, the F 75% / FRP 125 ratio of contraction force reducing and refractory lengthening dose is indicated. This relationship gives an explanation of the therapeutic breadth of the antiarrhythmic effect in isolated organs.
    The direct effect of active substances on the rate of contraction of the heart muscle (FRO) was tested on the spontaneously contracting isolated right atrium of the female individual of the white guinea pig weighing 300-400 g. In Table. 5, the FRQ of 75% indicates such a concentration, at which 20 minutes after the administration of the substance, an increase in the frequency of contraction is up to 75% of the initial value.
    From tab. 5, it can be seen that substances 1a-1e do not have an undesirable negative inotropic effect and, at very low concentrations, exhibit an antiarrhythmic effect that reduces the heart rate.
    In tab. Figure 5 shows the effect on the contractile frequency (FRQ) of the spontaneously contracting right atrium of the guinea pig, as well as on the contractile force (F) and the functional refractory period (FRP) of the electrically excited left atrial of the guinea pig.
    From the data table. 5, it follows that compounds 1a-1e significantly exceed the structural analogue M, M-9,9-tetrametes1 diazabicyclo (3.3.1) nonane in therapeutic latitude and can be: used for ischemic heart disease, arrhythmias and heart failure, pharmacological action in doses of 0.10 mg / kg. These substances are administered enterally or parenterally. Examples 68 describe pharmaceutical formulations and their preparation.
    Example 6. Tablets. Composition, including: active substance (1a ditartrate) 20J corn starch 30; lactose 55; crlidon 25 5; magnesium stearate 2; Hydrated Ricin Oil 1, Preparation Steps. The active substance is mixed in a mixer with corn starch and finely ground lactose. The resulting mixture is moistened with a 20% solution of polyrhenylpyrrolidone (collidon 25, Fa. BA.F) in Isopropanol. If necessary, isopropanol is added, the Wet granulate is sieved through a sieve with a hole diameter of 2 mm, dried at 0 ° C and then sieved directly through a sieve with a hole diameter t mm. After mixing the granulate with the stearate
    magnesium and hydrogenated ricin
    the oil is compressed into tablets of 113 mg, so that each tablet contains 20 mg of active substance.
    Example 7. Capsules. Composition, including: active substance (1a, ditartrate) 20; corn starch 20; lactose 45; Kollidon 3; magnesium stearate., 1,5, - aerosil 200 0.5.
    Stages of preparation.
    The active substance is mixed with corn starch and finely divided lactose in a blender. The resulting mixture is moistened with a 20% solution of polyvinylpyrrolidone (Kollidon 25) in isopropanol. If necessary, isopropanol is added. The wet granulate is sieved through a sieve with a hole diameter of 1.6 mm, dried at 40 ° C and immediately thereafter sieved through a sieve with a hole diameter of 1 mm. After mixing the granules with magnesium stearate and silica airgel / aeroel 200 Fa. Degussa) is filled automatically with a mixture of 90 mg of gelatin capsules of size 4, so that each capsule contains 20 mg of active substance.
    Example 8. Ampoules. Composition on 1 ampoule, mg: active substance (1a, ditertirat) 5; sodium chloride 16J water for injection - up to 2 ml. Stages of preparation.
    权利要求:
    Claims (1)
    [1]
    Sodium chloride is dissolved in water for injection, the active substance is added and dissolved with stirring. A sufficient amount of water for injection is added to the final 1272989 volume. The mixture is filtered through a membrane filter of 0.2-0.25. Ampoules of heat-resistant glass are placed at 2.15 MP and sealed. At 121 ° C for 30 minutes steam sterilized. At the same time, 2 ml of the solution for injections contain 5 mg of the active substance. The invention of the method for producing diazabicyc (3,3,1) nonanes of the general formula Pgm (k-Kg where R, and Rj are independent of each other C-Su-alkylene with the proviso that R, -R4 in total contain at least five carbon atoms, in which the general formula Rl- (, (f R, -R4) has the indicated values, reacts with the metal complex hydride in environment of an inerratolutive, such as ether
     the sodium bis (2-methoxyethoxy) dihydroaluminate is used as a reducing agent instead of lithium aluminihydride, the reaction is carried out in toluene.
    Diethylene glycol dimethyl ether
    Triethylene glycol dimethyl ether
    Used in the form of ditartrat.
    12729898
    table 2
    Table3
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1272989A3|1986-11-23|Method of producing diazabicyclo | nonanes
    JP2755403B2|1998-05-20|Compounds for the treatment of Alzheimer's disease
    WO1981001285A1|1981-05-14|Substituted carboxylic ceto-acids,process for the preparation thereof,use thereof and medicinal compositions containing them
    US4035366A|1977-07-12|1-Benzal-1,2,3,4-tetrahydro-isoquinolinium-theophylline-7-acetates
    US3923994A|1975-12-02|Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity
    SU1609453A3|1990-11-23|Method of producing derivatives of gidantoine
    US3966745A|1976-06-29|Vinvamine series cycloalkyl-alkyl esters
    DE2427207A1|1975-01-09|PROCESS FOR THE PREPARATION OF CONDENSED PYRRENE MERCAPTO COMPOUNDS
    US3137621A|1964-06-16|Method of treating colic with trihydroxyacetophenones
    US3781434A|1973-12-25|Methods of producing antiarthritic activity using 3-substituted phenyl-2-thio-1,3-thiazane-2,4-dione
    US4094988A|1978-06-13|Method of treating gastric ulcers using 5,6-dihydro-1,4-dithiinoxides
    US4415577A|1983-11-15|Bis-sparteine derivatives and method of using same in therapy
    US3879427A|1975-04-22|Derivatives of polycyclic gamma-pyrones
    EP0035734B1|1983-09-21|1-|2-hydroxy-3-alkinyl-amino propanes and processes for their manufacture
    DE2632951A1|1977-02-10|Purine |-deoxy |-alkylidene ribofuranonic acid derivs. - with cardiovascular and metabolic activity
    GB2051801A|1981-01-21|New compound with laxative activity, pharmaceutical compositions which contain it, and a process for its preparation
    DE3231088A1|1983-03-10|-cis-2,8-Dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido-|indo le, its preparation and pharmaceutical compositions, in particular antiarrhythmics
    SU598892A1|1978-03-25|Beta-| ethylamide 5-n-butyl-2-pyridinecarboxylic acid hydrochloride possessing antiarrhythmic effect
    DE2025286C3|1976-10-21|Ajmaline derivatives
    DE3316155C2|1992-11-26|
    CA1069507A|1980-01-08|Compound, named n-oxy-ajmaline, the method of preparing it and its application in therapeutics
    SAKAI et al.1987|Antiarrhythmic effects of a novel diamine derivative, AN-132, on several animal models of cardiac arrhythmias
    RU2068261C1|1996-10-27|Antiarrythmic agent
    US3709995A|1973-01-09|Method of producing gastrointestinal spasmolytic activity with alkylphenoxypoly|ethanols
    US2978457A|1961-04-04|5-acylamido-4-substituted-thiazole-2-sulfonamides having diuretic properties
    同族专利:
    公开号 | 公开日
    FI76338B|1988-06-30|
    IL69751D0|1983-12-30|
    US4742172A|1988-05-03|
    DK422583A|1984-03-19|
    CA1259998C|1989-09-26|
    GR78722B|1984-10-02|
    IL69751A|1986-10-31|
    HU191096B|1987-01-28|
    NO160516C|1989-04-26|
    DK422583D0|1983-09-16|
    DD213923A5|1984-09-26|
    NZ205627A|1985-11-08|
    NO833346L|1984-03-19|
    FI833339A|1984-03-19|
    IE832186L|1984-03-18|
    EP0250903B1|1991-11-27|
    UA817A1|1993-12-15|
    FI76338C|1988-10-10|
    JPH0670056B2|1994-09-07|
    NO160516B|1989-01-16|
    JPS5970686A|1984-04-21|
    AU1920683A|1984-03-22|
    DK165833C|1993-06-21|
    CS389891A3|1992-07-15|
    EP0250903A2|1988-01-07|
    IE57580B1|1993-01-13|
    DK165833B|1993-01-25|
    AU564910B2|1987-09-03|
    EP0103833B1|1989-08-16|
    ES525653A0|1984-06-01|
    FI833339A0|1983-09-19|
    CA1254209A1|1989-05-16|
    ZA836185B|1984-04-25|
    PT77344B|1986-03-11|
    AT45579T|1989-09-15|
    PH20768A|1987-04-10|
    PT77344A|1983-10-01|
    EP0250903A3|1988-03-09|
    DE3382466D1|1992-01-09|
    MX9202996A|1992-07-01|
    DE3234697A1|1984-03-22|
    EP0103833A2|1984-03-28|
    DE3380409D1|1989-09-21|
    ES8405398A1|1984-06-01|
    EP0103833A3|1984-11-28|
    JPH05247039A|1993-09-24|
    AT69817T|1991-12-15|
    US4550112A|1985-10-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE2428792A1|1974-06-14|1976-01-02|Knoll Ag|NEW ANTIARRHYTHMICS|
    LU76173A1|1976-11-11|1978-07-10|
    DE2658558A1|1976-12-23|1978-06-29|Bayer Ag|DIAZABICYCLO NONANE, METHOD FOR MANUFACTURING IT AND ITS USE AS A MEDICINAL PRODUCT|
    DE2726571A1|1977-06-13|1978-12-21|Basf Ag|NEW BISPIDINE DERIVATIVES, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM|DE3529872A1|1985-08-21|1987-02-26|Kali Chemie Pharma Gmbh|NEW TETRAOXY CONNECTIONS|
    WO1989000158A1|1987-07-02|1989-01-12|Pfizer Inc.|Bridged-diazabicycloalkyl quinolone carboxylic acids and esters|
    DE3722134A1|1987-07-04|1989-01-19|Kali Chemie Pharma Gmbh|3-SULFONYL-3,7-DIAZABICYCLONONANE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    PT88381B|1987-09-09|1995-07-06|Kali Chemie Pharma Gmbh|PROCESS FOR THE PREPARATION OF NEW COMPOUNDS 3,7-DIAZABICYCLONONANO, AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS|
    DE4019080A1|1990-06-15|1991-12-19|Kali Chemie Pharma Gmbh|Use of new and known 3,7-di:aza-bi:cyclononane derivs. - as diuretics for treating oedema, coronary insufficiency and hypertonia|
    DE4139763A1|1991-12-03|1993-06-09|Kali-Chemie Pharma Gmbh, 3000 Hannover, De|CRYSTALLINE FUMAR ACID SALTS OF 9,9-ALKYLENE-3,7-DIAZABICYCLONONAN COMPOUNDS AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    DE4402933A1|1994-02-01|1995-08-03|Kali Chemie Pharma Gmbh|New drugs containing 3-benzoyl-3,7-diazabicyclo [3,3,1] nonane compounds|
    DE4421324A1|1994-06-17|1995-12-21|Kali Chemie Pharma Gmbh|New drugs containing 3,7-diazabicyclo [3,3,1] nonane compounds|
    SE9704709D0|1997-12-17|1997-12-17|Astra Ab|Pharmaceutically active compounds|
    US20050004113A1|1999-06-16|2005-01-06|Astrazeneca Ab|New bispidine compounds useful in the treatment of cardiac arrhythmias|
    US20040229900A1|1999-06-16|2004-11-18|Astrazeneca Ab|Bispidine compounds useful in the treatment of cardiac arrythmias|
    SE9902270D0|1999-06-16|1999-06-16|Astra Ab|Pharmaceutically active compounds|
    AR030756A1|2000-10-02|2003-09-03|Astrazeneca Ab|COMPOUND OF OXABISPIDINE USEFUL IN THE TREATMENT OF CARDIAC ARRITMIES|
    SE9904765D0|1999-12-23|1999-12-23|Astra Ab|Pharmaceutically useful compounds|
    SE0002603D0|2000-07-07|2000-07-07|Astrazeneca Ab|New compounds|
    US6808924B1|2000-07-11|2004-10-26|Claudia Lanari|Mouse mammary tumor lines expressing estrogen and progesterone receptors|
    SE0003795D0|2000-10-20|2000-10-20|Astrazeneca Ab|Pharmaceutically useful compounds|
    SE0100326D0|2001-02-02|2001-02-02|Astrazeneca Ab|New compounds|
    DE10131217A1|2001-06-28|2003-01-09|Solvay Pharm Gmbh|3-phenyl-3,7-diazabicyclo 3,3,1 nonane compounds and processes for their preparation and medicaments containing these compounds|
    TW200418468A|2002-11-18|2004-10-01|Solvay Pharm Gmbh|Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events|
    US20050054667A1|2003-07-21|2005-03-10|Solvay Pharmaceuticals Gmbh|Method of treating or inhibiting anti-arrhythmic events in male human patients|
    MXPA06000796A|2003-07-21|2006-04-07|Solvay Pharm Gmbh|Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients.|
    WO2005030207A1|2003-09-26|2005-04-07|Solvay Pharmaceuticals Gmbh|Use of 3, 7-diazabicyclononane compounds for the treatment of brugada syndrome|
    SE0302775D0|2003-10-20|2003-10-20|Astrazeneca Ab|Chemical compound and assay|
    CA2609938A1|2005-06-13|2006-12-21|Astrazeneca Ab|New oxabispidine compounds for the treatment of cardiac arrhythmias|
    SE0401539D0|2004-06-15|2004-06-15|Astrazeneca Ab|New compounds|
    SE0401540D0|2004-06-15|2004-06-15|Astrazeneca Ab|New compounds|
    US10399926B1|2018-08-01|2019-09-03|Divi's Laboratories Ltd.|Process for the preparation of gabapentin|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19823234697|DE3234697A1|1982-09-18|1982-09-18|NEW DIAZABICYCLONONANA|LV920132A| LV5139A3|1982-09-18|1992-09-24|Substance for the production of diazabicyclo--nonanes|
    LTRP154A| LT2012B|1982-09-18|1992-10-14|THE DIAZABICICNONANA RECEIVING BUDGET|
    [返回顶部]